Drug intelligence / Profile preview

OVV-01

Development stage: Phase 2
Lead developer: Li Ning
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral Injection

Overview

OVV-01 is an oncolytic virus injection that selectively replicates in tumor cells. It has been investigated as both a monotherapy and in combination with immune checkpoint inhibitors (pembrolizumab or atezolizumab) or trained immunity NK (tiNK) cell injection (IBR900) for the treatment of advanced solid tumors. Early phase studies have shown objective response rates ranging from 13.0% to 27.3%, with the treatment being generally well-tolerated.

Other names: oncolytic virus injection

Beyond the preview

Go deeper on OVV-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVV-01.

Explore the full profile